- Home
- GXAI vs SLXN Comparison
GXAI vs SLXN Comparison
Compare GXAI & SLXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GXAI
- SLXN
- Stock Information
- Founded
- GXAI 2021
- SLXN 2008
- Country
- GXAI United States
- SLXN Israel
- Employees
- GXAI N/A
- SLXN N/A
- Industry
- GXAI
- SLXN
- Sector
- GXAI
- SLXN
- Exchange
- GXAI Nasdaq
- SLXN NYSE
- Market Cap
- GXAI 10.1M
- SLXN 7.3M
- IPO Year
- GXAI 2023
- SLXN N/A
- Fundamental
- Price
- GXAI $1.49
- SLXN $0.81
- Analyst Decision
- GXAI
- SLXN Strong Buy
- Analyst Count
- GXAI 0
- SLXN 1
- Target Price
- GXAI N/A
- SLXN $5.00
- AVG Volume (30 Days)
- GXAI 122.3K
- SLXN 147.1K
- Earning Date
- GXAI 08-12-2025
- SLXN 08-21-2025
- Dividend Yield
- GXAI N/A
- SLXN N/A
- EPS Growth
- GXAI N/A
- SLXN N/A
- EPS
- GXAI N/A
- SLXN N/A
- Revenue
- GXAI $27,740.00
- SLXN N/A
- Revenue This Year
- GXAI N/A
- SLXN N/A
- Revenue Next Year
- GXAI N/A
- SLXN N/A
- P/E Ratio
- GXAI N/A
- SLXN N/A
- Revenue Growth
- GXAI 9987.27
- SLXN N/A
- 52 Week Low
- GXAI $1.00
- SLXN $0.58
- 52 Week High
- GXAI $7.50
- SLXN $41.85
- Technical
- Relative Strength Index (RSI)
- GXAI 60.96
- SLXN N/A
- Support Level
- GXAI $1.30
- SLXN N/A
- Resistance Level
- GXAI $1.49
- SLXN N/A
- Average True Range (ATR)
- GXAI 0.08
- SLXN 0.00
- MACD
- GXAI 0.01
- SLXN 0.00
- Stochastic Oscillator
- GXAI 86.21
- SLXN 0.00
About GXAI Gaxos.ai Inc.
Gaxos.AI Inc is revolutionizing the way humans interact with artificial intelligence. The company offers applications related to mental and physical well-being, coaching, and gaming. The group is committed to tackling contemporary challenges such as how to live healthier and how to live longer. In addition to offering human-centered solutions, the company uses empathetic and AI technologies.
About SLXN BIOMOTION SCIENCES
Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.